<DOC>
	<DOCNO>NCT01866163</DOCNO>
	<brief_summary>The purpose trial compare efficacy treatment LEO 90100 treatment vehicle 4 week subject psoriasis vulgaris .</brief_summary>
	<brief_title>LEO 90100 Compared Vehicle Subjects With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A clinical diagnosis psoriasis vulgaris least 6 month duration involve trunk and/or limbs Psoriasis vulgaris trunk and/or limb ( exclude psoriasis genitals skin fold ) involve 230 % Body Surface Area ( BSA ) An Investigator 's Global Assessment disease severity ( IGA ) least mild Day 0 ( Visit 1 ) A modify PASI ( mPASI ) score least 2 Day 0 ( Visit 1 ) A target lesion minimum 5 cm long axis preferably locate extensor surface elbow knee , score least 1 redness , thickness scaliness , least 4 total Investigator 's Assessment Severity Target Lesion Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : etanercept within 4 week prior randomisation adalimumab , infliximab within 8 week prior randomisation ustekinumab within 16 week prior randomisation product within 4 weeks/5 halflives prior randomisation ( whichever longer ) Systemic treatment therapy possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , methotrexate , ciclosporin immunosuppressant ) within 4 week prior randomisation . Subjects receive treatment nonmarketed drug substance ( i.e . drug yet make available clinical use follow registration ) within 4 weeks/5 halflives ( whichever longer ) prior randomisation . PUVA therapy within 4 week prior randomisation . UVB therapy within 2 week prior randomisation . Topical antipsoriatic treatment trunk limb ( except emollient ) within 2 week prior randomisation . Topical treatment face , scalp skin fold corticosteroid , vitamin D analogue prescription shampoo within 2 week prior randomisation . Planned initiation , change , concomitant medication could affect psoriasis vulgaris ( e.g . beta blocker , antimalarial drug , lithium , ACE inhibitor ) trial . Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis . Previously randomise trial previously conduct trial LEO 90100 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>